Abstract:Abstract Unrelated donor allogeneic hematopoietic stem cell transplantation (URD-HSCT) can potentially cure a variety of hematological malignancies. Until now, there were 140 cases of URD-HSCT in our bone marrow transplantation center, and we would retrospectively analyze the results of 128 patients received URD-HSCT between Nov. 1998 and May. 2006. The median age of all patients was 28 years (range 8–52 years), 27 patients with ALL in CR1, 28 patients with AML (26 in CR1 and 2 in CR2), 64 patients with CML (59 in CP, 1 in AP and 4 in BP), 8 patients with MDS, and 1 patient with MM. 113 patients were received Bu/Cy2 regimen as conditioning with busulfan 16mg/kg plus cyclophosphamide 120mg/kg, while other 5 patients with CML were received reduced intensity conditioning (RIC) regimen consisted of fludarabine (30mg/m2/d), busulfan (3.2mg/kg/d, i.v.) and ATG (5mg/kg/d). Graft with a median number of total nucleated cells was 3.45×108/kg (range 1.72–10.50×108/kg), including CD34+ cells 4.77×106/kg (range 0.72–9.92×106/kg) and CFU-GM 2.73×105/kg (range 1.46–7.91×105/kg). 110 patients were given MMF (0.5g/d), combined with CsA (3mg/kg/d) and short course MTX (10mg/m2/d) to prevent aGVHD. 18 patients received additional anti-CD25 monoclonal antibody 50mg/d on day 0, +4. Lipo protaglandin E1 was given to prevent SOS and CMV-PP65 antigen was monitored after the transplantation and ganciclovir was used to prevent CMV infection. Hemopoietic recovery was observed in 123 evaluable patients, and the median time to achieve ANC>0.5×109/L was 17 days (range 12–31 days), platelets >20×109/L was 24 days (range 8–140 days). aGVHD developed in 69 (56.10%) patients; aGVHD of grade I-II were observed in 53 (43.09%) patients and the severe aGVHD of grade III-IV were observed in 16 (13.01%) patients. cGVHD developed in 53 (46.49%) patients with 46 (40.35%) limited and 7 (6.14%) extensive. In group (n=110) which received MMF combined with CsA and MTX as aGVHD prophylaxis, aGVHD were observed in 60 (54.55%) patients with grade I-II 42.73% and grade III-IV 11.82%. While in group (n=18) which received additional anti-CD25 monoclonal antibody, aGVHD were observed in 7 (46.7%) patients with grade I-II 6 (33.3%) and grade III-IV 3 (16.67%). There was no significant difference between two regimen of aGVHD prophylaxis. Early TRM of all patients was 10.94% at 100 days after transplant. After a median follow-up of 13.2 months (range 1.3–92 months), clinical relapse were detected in 8 patients. By Kaplan-Meier method, the accumulative probability of 5-year overall survival of all patients was 60.98±4.52%, and which of ALL, AML, CML, MDS were 68.65±9.21%, 61.61±9.74%, 56.95±6.50% and 75.00±15.31%, respectively. 4 of 5 patients received reduced intensity URD-HSCT with follow-up of 7.3 months (range 3.0–10.3 months) experienced successful engraftment, and no aGVHD developed while cGVHD occurred in 2 cases, all patients achieved disease free survival. To further examined the impact of HLA matching on GVHD and survival, we compared the outcomes of the HLA-matched group (n=82) and HLA 1–2 alleles disparity mismatched group (n=46). aGVHD were observed in 38 (46.34%) patients in HLA-matched group and 31 (67.39%) patients in HLA-mismatched group (P<0.05), respectively. The survival of HLA-matched and HLA-mismatched group were 69.14% and 52.17% (P<0.05) respectively. URD-HSCT could be one of choice in patients with ALL, AML, CML, MDS, and HLA class I and class II matching would be associated with the outcomes of URD-HSCT.

Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases

Review article: Stem cell transplantation for the treatment of gastrointestinal diseases--current applications and future perspectives

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Outcomes Of Unrelated Donor Hematopoietic Stem Cell Transplantation For Hematological Malignancy: A Single Center'S Experience.

Donor Lymphocyte Infusion after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies.

Mesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage

Haemopoietic Stem Cell Transplantation--an Evolving Treatment for Severe Autoimmune and Inflammatory Diseases in Rheumatology, Neurology and Gastroenterology.

Autologous Hematopoietic Stem Cell Transplantation for Crohn'S Diseases - 5 Cases Report.

Retrospective and follow-up study on autologous haematopoietic stem cell transplantation in ten patients with refractory inflammatory bowel disease

Hematopoietic stem cell transplantation therapy for refractory' Crohn disease: A systematic review and meta-analysis

HLA-Haploidentical Related Hematopoietic Stem Cell Transplantation and Mesenchymal Stem Cell Transplantation in Patients with Hematologic Malignancies.

Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn’s Disease: Efficacy in a Single-Centre Cohort

Update on the Use of Mesenchymal Stem Cells and their Products in Hematopoietic Stem Cell Transplantation

The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease

Harnessing and honing mesenchymal stem/stromal cells for the amelioration of graft-versus-host disease

Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for non-malignant diseases

International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant

Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD

Immunotherapy by allogeneic stem cell transplantation

HLA-haploidentical Stem Cell Transplantation for Hematologic Malignancies.

Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders